A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Rezumatul știrii
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Urmărește cele mai noi știri de la publicații de încredere, cu rezumate scurte. Deschide sursa originală pentru detalii.